Archivum Immunologiae et Therapiae Experimentalis

, Volume 63, Issue 6, pp 405–414 | Cite as

Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases

  • Tetsuya Yamagata
  • Jill Skepner
  • Jianfei YangEmail author


Interleukin (IL)-17-producing T cells, especially T helper (Th)17 cells, play a critical role in the pathogenesis of a variety of autoimmune inflammatory diseases. The pathogenic function of Th17 cells results from their production of Th17 effector cytokines, namely IL-17 (or IL-17A), IL-17F, IL-22 and IL-26. The importance of IL-17 has been demonstrated by antibody neutralization studies in both animal models of autoimmune diseases as well as in human clinical trials. This review highlights the current knowledge of the clinical aspects of the Th17 cytokines as well as therapeutic antibodies against IL-17, IL-17F, IL-17 receptor, IL-22, IL-26 and granulocyte macrophage colony-stimulating factor for the future treatment of autoimmune inflammatory diseases.


Th17 IL-17 IL-22 IL-26 Autoimmune disease 


Upon antigen stimulation by MHC class II on antigen-presenting cells and with the appropriate cytokine milieu, naïve CD4+ T helper (Th) cells are differentiated into subsets, including Th1, Th2, and Th17 cells. Th1 cells typically produce interferon (IFN)-γ, Th2 cells produce interleukin (IL)-4 and IL-13, and Th17 cells produce IL-17A/F, IL-22, IL-26, IL-21 and granulocyte macrophage colony-stimulating factor (GM-CSF). Th17 cells were identified by and named for their production of IL-17 (now formally named IL-17A). IL-17-producing Th17 cells were first found to be much more pathogenic than IFN-γ-producing Th1 cells in an adoptive transfer model of experimental autoimmune encephalitis (EAE), an animal model of human multiple sclerosis (Langrish et al. 2005).

Th17 cell differentiation from naïve CD4+ T cells is induced by T cell receptor activation and costimulation with the inflammatory cytokines IL-6, transforming growth factor β, IL-21, IL-1β and IL-23 (Bettelli et al. 2006; Veldhoen et al. 2006). The differentiation of Th17 cells requires the retinoic acid receptor-related orphan nuclear receptor RORγt (Ivanov et al. 2006), which is induced in activated naïve T cells upon stimulation with the STAT3-activating cytokines IL-6 and IL-1β (Acosta-Rodriguez et al. 2007). In addition to Th17 cells, RORγt expression has been described in CD8+ Tc17 cells and subsets of γδ T cells characterized by IL-17 expression. T cells lacking RORγt (Rorc −/−) or STAT3 fail to generate Th17 cells (Ivanov et al. 2006). Several other transcription factors also contribute to the regulation of Th17 cell development. For example, BATF and IRF4 cooperatively contribute to the initial chromatin accessibility, and in combination with STAT3 initiate a transcriptional program that is tuned by RORγt (Ciofani et al. 2012). RORγt has been demonstrated to be the master transcription factor of Th17 cells. RORγt small molecular inhibitors have been generated for the treatment of several autoimmune diseases (Skepner et al. 2014, 2015; Yang et al. 2013).

Th17 cytokines are important not only for protective immunity against extracellular pathogens including Klebsiella pneumonia and Pneumocystis carinii (Happel et al. 2005; Rudner et al. 2007; Ye et al. 2001a), but also for the clearance of intracellular pathogens such as Mycobacteria tuberculosis (Khader et al. 2007). IL-17R-deficient mice have been used to demonstrate that IL-17A is involved in the host defense to Candida albicans and K. pneumonia fungal infections (Huang et al. 2004; Ye et al. 2001b).

In addition to the important role in protective immunity, Th17 cells and Th17 effector cytokines play a critical role in the pathogenesis of a variety of autoimmune inflammatory diseases. In this article, we review the role of Th17 effector cytokines in the pathogenesis of autoimmunity and the current progress and strategies of targeting the Th17 effector cytokines IL-17A, IL-17F, IL-22 and IL-26.

Interleukin 17

IL-17 Cytokine Family and IL-17 Receptors

IL-17 was first cloned two decades ago as CTLA-8 from T cells by Rouvier et al. (1993). Later, Yao et al. (1995a) discovered that CTLA-8 acts as a novel cytokine and binds to a novel cytokine receptor. CTLA-8 was then named IL-17. IL-17 is believed to be a proinflammatory cytokine since it stimulates epithelial, endothelial, and fibroblastic cells to express the proinflammatory molecules IL-6, IL-8, granulocyte colony-stimulating factor, prostaglandin E2 and intracellular adhesion molecules-1 (Fossiez et al. 1996; Yao et al. 1995b). IL-17 was re-named IL-17A since there are at least six IL-17 family members: IL-17A, IL-17B (also known as IL-20), IL-17C, IL-17E (also known as IL-25) and IL-17F. These cytokines bind to different receptors IL-17RA, IL-17RB, IL-17RC, and IL-17RE. IL-17A is most similar to IL-17F, sharing 60 % amino acid identity. In addition, the signaling of both IL-17A and IL-17F requires both IL-17RA and IL-17RC (Gaffen 2009; Miossec and Kolls 2012). The importance of IL-17 was significantly emphasized after the discovery of IL-17-producing Th17 cells (Langrish et al. 2005).

Source of IL-17

IL-17A and IL-17F are mainly expressed in T cells whereas IL-17B, IL-17C, and IL-17E are more broadly expressed in other cell types. In cells involved in the adaptive immune response, CD4+ Th17 cells produce both IL-17A and IL-17F (Korn et al. 2009; Langrish et al. 2005; Leppkes et al. 2009; Seiderer et al. 2008). In addition to Th17 cells, some subset of CD8+ T cells express Th17 cytokines such as IL-17A, IL-17F and IL-22 (Kondo et al. 2009; Res et al. 2010; Skepner et al. 2014), and these cells are defined as Tc17 cells. In the cells of innate immunity, γδ T cells produce IL-17 upon stimulation with IL-1β and IL-23 (Sutton et al. 2009). IL-17-producing γδ T cells share characteristic features with Th17 cells, such as expression of chemokine receptor 6 (CCR6), RORγt, and IL-23 receptor (Martin et al. 2009). Lymphoid tissue-inducer (LTi) cells also express RORγt and produce IL-17A and IL-22 upon stimulation with IL-23, yeast cell wall product zymosan, or Toll-like receptor (TLR)2 (Crellin et al. 2010; Cupedo et al. 2009; Takatori et al. 2009), indicating LTi cells play important roles in host defense and inflammation. Further, IL-17 can be produced by invariant NKT cells upon synthetic [α-galactosylceramide (α-GalCer) or PBS-57] as well as natural (lipopolysaccharides or glycolipids derived from Sphingomonas wittichii and Borrelia burgdorferi) ligand stimulation (Michel et al. 2007). In the absence of IL-10R signaling, macrophages express high level of IL-17 and IL-22 (Gu et al. 2008). Synovial mast cells in rheumatoid arthritis have been reported to release IL-17 (Suurmond et al. 2011). For further reading regarding innate IL-17-producing cells, see the review by Daniel Cua (Cua and Tato 2010).

IL-17 and Autoimmune Diseases

Th17 cells and IL-17A are critical for the development of EAE (Ivanov et al. 2006). Microarray analysis of multiple sclerosis lesions obtained at autopsy revealed an increase in IL-6 and IL-17 transcripts (Lock et al. 2002). In mice, an anti-IL-17A auto-vaccine prevented the development of EAE (Uyttenhove and Van 2006). In rheumatoid arthritis (RA), numerous reports have demonstrated a correlation between disease activity, IL-17 cytokine level and the number of Th17 cells. IL-17 is increased in RA sera and synovial fluid, and is present in the T cell-rich areas of the synovium (Lubberts 2015). Increased levels of IL-17 and tumor necrosis factor (TNF)-α mRNA expression in synovium from early stage RA are predictive of more severe joint damage progression (Sarkar and Fox 2010). Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen-induced arthritis and aggravates joint destruction (Lubberts et al. 2002). IL-17 receptor deficiency results in impaired synovial expression of IL-1β and matrix metalloproteinases 3, 9, and 13, and prevents cartilage destruction during arthritis (Koenders et al. 2005). Th17 cells and Th17 cytokines are also important for the pathogenesis of several other inflammatory diseases including psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, systemic lupus erythematosus, asthma and chronic obstructive pulmonary disease (for review, see reference Miossec and Kolls 2012 and Robinson et al. 2013). Thus, blocking IL-17/IL-17R pathway is believed to be effective ways for the treatment of autoimmune inflammatory diseases.

Blocking IL-17/IL-17R Pathway

There are several ways to block the IL-17 pathway. Neutralizing IL-17 is an obvious choice since IL-17 is a dominant Th17 cytokine. Indeed, Secukinumab (AIN457), Ixekizumab (LY2439821), SCH-900117, and RG4934 have been developed as neutralizing monoclonal antibodies against IL-17. Since IL-17A and IL-17F can form IL-17A/IL-17F heterodimers, RG7624 was developed to interact with both IL-17A and IL-17F, and theoretically might also target IL-17A and IL-17F homodimers as well as IL-17A/IL-17F heterodimers. Targeting IL-17 receptor is another way to block the IL-17/IL-17R interaction. Brodalumab (AMG827) binds to IL-17RA, a subunit of functional IL-17R together with IL-17RC, and inhibits IL-17 binding to the functional receptor complex. Figure 1 illustrates different approaches of targeting Th17 effector cytokines.
Fig. 1

Antibodies targeting major Th17 signature cytokines and their related receptors. The antibodies against these molecules block the binding of the cytokines to their receptors and inhibit the downstream signalings and proinflammatory gene expression responses. The antibodies with names are being developed or in the clinic. The antibodies without names are potential targets for specific inhibitions. Antibodies against IL-20RA could block IL-26 binding to the receptor, but may also block other cytokines using this receptor such as IL-19, IL-20 and IL-24

Targeting the IL-17/IL-17R pathway with these antibodies in different autoimmune diseases has allowed for the assessment of the pathogenic role of this cytokine pathway in each disease. In psoriasis, a Phase II study with a single injection of Secukinumab reduced the surface area covered by skin lesions as well as the number of IL-17A-positive cells in skin biopsy samples (Hueber et al. 2010). Another Phase II psoriasis study with multiple injections of Ixekizumab showed significant effect as early as 1 week and the effect was sustained through 20 weeks (Leonardi et al. 2012). Targeting IL-17RA with Brodalumab also showed significant improvement in plaque psoriasis at 12 weeks (Papp et al. 2012). Phase III studies have been completed for Secukinumab (Langley et al. 2014), Ixekizumab ( Identifier: NCT01597245) and Brodalumab ( Identifier: NCT00975637) with the results still pending release. The consistent results from Phase II trials indicate that the IL-17/IL-17R pathway has clear pathological role in psoriasis (Mease 2015). In ankylosing spondylitis, a Phase II trial with Secukinumab rapidly reduced clinical and biological signs of moderate-to-severe ankylosing spondylitis, and demonstrated significant improvement in ASAS20 at 6 weeks (Baeten et al. 2013).

In an animal model of RA, treatment with a neutralizing anti-murine IL-17 antibody after the onset of collagen-induced arthritis reduced joint inflammation, cartilage destruction, and bone erosion (Lubberts et al. 2004). In a proof-of-concept study with RA patients, Secukinumab injection significantly reduced inflammation in the joints, and demonstrated improvements in ACR20, DAS28 and CRP scores (Hueber et al. 2010). These effects were seen rapidly after the first infusion, and the improvements sustained for up to 13 weeks after the second infusion, indicating that neutralizing IL-17A has the potential to rapidly suppress inflammation as well as provide sustained effect. A Phase I study with Ixekizumab in combination with oral disease-modifying antirheumatic drugs improved the signs, symptoms and DAS28 scores of RA, with no strong adverse safety signal. Percentages of ACR20, ACR50, and ACR70 responses as well as improvements in the ACR core set of measures were greater in Ixekizumab-treated patients than in placebo-treated patients at multiple time points (Genovese et al. 2010). Exploratory efficacy analyses in Phase IB with Brodalumab using ACR20 and DAS28 scores did not reveal significant clinical responses with moderate-to-severe RA patients (Martin et al. 2013). Further, the Phase II study with Secukinumab on RA patients with inadequate response to methotrexate did not achieve significant ACR20 response at 16 weeks (Genovese et al. 2013). Thus, the role of IL-17-IL17R pathway in RA warrants further studies (Lubberts 2015).

In inflammatory bowel disease (IBD), clinical trials of Brodalumab and Secukinumab for Crohn’s disease failed to improve disease symptoms, and even increased disease activity likely because IL-17 is involved in maintaining intestinal epithelial barrier function (Hueber et al. 2012; Symons et al. 2012). Thus, most anti-IL-17 monoclonal antibody trials now exclude IBD.

Taken together, preclinical and clinical evidence demonstrate a strong pathogenic role for the IL-17A/IL-17R pathway in psoriasis and ankylosing spondylitis, modest to equivocal role for RA, and a protective role in IBD. The role of the IL-17A/IL-17R pathway in other autoimmune/inflammatory diseases remains to be further investigated (Li et al. 2015).

Interleukin 22

IL-22 and IL-22 Receptors

IL-22 belongs to the IL-10 cytokine family and is mainly produced by T cells and innate lymphoid cells (ILCs) in humans. Th17 cells are believed to be the major source of T cell derived IL-22 (Liang et al. 2006; Zheng et al. 2007). Further studies characterized IL-22-producing cells as a new subset of Th cells name as Th22 cells (Duhen et al. 2009; Eyerich et al. 2009; Trifari et al. 2009). A subset of Th1 cells has also been shown to express IL-22 (Wolk et al. 2002). In addition, CD8+ T cells, γδ T cells and NKT cells have also been reported to express IL-22 (Witte et al. 2010).

IL-22 signals via a transmembrane receptor complex composed of two subunits: IL-22RA and IL-10RB (Kotenko et al. 2001; Xie et al. 2000). The IL-22RA subunit is not only utilized for IL-22 signaling, but is also used as a receptor subunit for two other members of the IL-10 cytokine family: IL-20 and IL-24. Unlike other cytokines secreted by Th17 cells, IL-22 (and IL-26) mainly targets non-hematopoietic cells. IL-22 exerts its effects mainly on epithelial cells that confer barrier function, such as skin, lung and intestine (Sonnenberg et al. 2011).

Physiological Role of IL-22

IL-22 binding to the IL-22 receptor complex induces the phosphorylation of STAT3. In addition to STAT3, weak activation of STAT1 and STAT5 has also been observed after IL-22 stimulation of cells expressing the IL-22 receptors (Lejeune et al. 2002; Wolk et al. 2004). Further, phosphorylation of MEK1/2, ERK1/2, p90RSK, JNK, and p38 kinase can be induced by IL-22 stimulation (Lejeune et al. 2002). IL-22 induces the expression of anti-microbial proteins of the β-defensin family (BD2, BD3), S100A family (S100A7, S100A8, S100A9), and regenerating islet-derived protein (REG) family (REG3β, REG3γ and REG1α) in keratinocytes, and epithelial cells from bronchia and intestine (Wolk et al. 2006; Zheng et al. 2008). In tracheal and colonic epithelial cells, IL-22 induces the expression of mucus-associated proteins, including mucin 1 (MUC1), MUC3, MUC10 and MUC13 (Aujla et al. 2008; Sugimoto et al. 2008). Further, IL-22 induces the expression of specific chemokines in epithelial cells, particularly chemokines with neutrophil-attracting properties including CXC-chemokine ligand 1 (CXCL1), CXCL2, CXCL5 and CXCL8 (Wolk et al. 2009). In addition, IL-22 may facilitate the epithelial repair process by increasing the expression of the extracellular matrix-degrading enzymes matrix metalloproteinase 1 (MMP1) and MMP3 (Boniface et al. 2005; Wolk et al. 2006), inhibiting the terminal differentiation of keratinocytes, and enhancing the proliferation of epithelial cells from the respiratory tract and the gut (Kumar et al. 2013).

IL-22 in Autoimmune Inflammatory Diseases

In psoriasis, IL-22 is increased in the blood of patients and its level strongly correlates with the disease severity (Wolk et al. 2006). IL-22 is highly expressed in psoriatic lesional skin but not in non-lesional skin or in the skin of healthy individuals (Wolk et al. 2004). The skin alterations observed in psoriasis are caused by inflammation-induced hyper-proliferation (i.e., acanthosis) and impaired differentiation of keratinocytes, consistent with observations of the biological activity of IL-22 in vitro. This alteration is attributed to the excess activity of IL-22 to regenerate the breached barrier (Wolk et al. 2004). Induction of neutrophil recruitment to the lesion contributes to the further destruction of tissue structure (Wolk et al. 2009). IL-22-deficient mice have shown reduced acanthosis and skin infiltration of granulocytes induced by intradermal injection of IL-23 (Zheng et al. 2007).

In RA patients, high levels of plasma IL-22 and increased numbers of IL-22-expressing T cells have been observed (Leipe et al. 2011). The increased plasma IL-22 level positively correlates with disease severity and disease progression (Da Rocha et al. 2012; Zhang et al. 2011). Furthermore, IL-22 mRNA is expressed in synovial tissues and mononuclear cells in the synovial fluid of RA patients (Ikeuchi et al. 2005). However, the pathogenic contribution of IL-22 in experimental models of arthritis is not well established (Sarkar et al. 2013).

In IBD, the plasma level of IL-22 and the number of IL-22-producing CD4+ T cells in the blood were found to be elevated in Crohn’s disease and were correlated with disease severity (Wolk et al. 2007). The number of IL-22-producing CD4+ T cells in the blood was also correlated with the extent of mucosal inflammation (Dige et al. 2013). Thus, IL-22 expression correlates with Crohn’s disease. However, studies in mice have demonstrated mixed effects of IL-22 in the pathogenesis of colitis. In a Th2 cell-mediated ulcerative colitis-like model, the increased expression of IL-22 conferred a protective effect (Sugimoto et al. 2008). A similar effect was observed in a mouse model of colitis induced by the transfer of naive CD4+ T cells into mice deficient in RAG expression. Transfer of IL-22-deficient naive CD4+ T cells into IL22−/−Rag1−/− mice exacerbated the colitis, suggesting protective role of IL-22 secreted from T cells (Zenewicz et al. 2008). However, in a similar model, transfer of IL-22-deficient memory CD4+ T cells into Rag1−/− mice resulted in amelioration of the phenotype, suggesting a pathogenic role for IL-22 (Kamanaka et al. 2011). Accordingly, the precise role of IL-22 in colitis may be context-dependent.

Targeting IL-22/IL-22R Pathway

Blocking IL-22/IL-22R appears to be a legitimate path (Fig. 1) for the treatment of psoriasis. In the imiquimod (TLR7 and TLR8 agonist)-induced skin inflammation model, the tissue alteration was significantly reduced in both IL-22-deficient mice and mice treated with neutralizing IL-22 antibodies (Van Belle et al. 2012). Clinical trials have been conducted with an anti-human IL-22 antibody [ILV-094 (fezakinumab), Pfizer] on healthy subjects, followed by a small number of psoriasis subjects. Unfortunately, the study was discontinued in 2011 for not being able to meet the primary end points (ILV-095) ( Identifier: NCT01010542). The anti-IL-22 antibody ILV-094 is currently being tested in atopic dermatitis patients ( Identifier: NCT01941537). There was also an effort to target IL-22R by developing an anti-IL-22R antibody (ZCYTOR11) for the treatment of psoriasis, but the development has ceased. Another attempt to block IL-22R signaling was ARGX112, an antibody that neutralizes both IL-20 and IL-22 mediated signaling through blockade of their common receptor, IL-22RA. This antibody has proven to be highly effective in preclinical models of chronic skin inflammation ( Thus, the effect of inhibiting the IL-22/IL-22R pathway in psoriasis remains to be determined.

A clinical trial has been conducted with the anti-human IL-22 antibody ILV-094 (fezakinumab) in RA patients on a stable background of methotrexate. The study was completed in 2011 but the results have not been published ( Identifier: NCT00883896). The contribution of IL-22 in the pathogenesis of RA remains to be explored. Furthermore, IL-22 was recently suggested to be involved in pathogenesis of enthesitis based on data from a mouse model (Sherlock et al. 2012). Therefore, targeting IL-22/IL-22R pathway might be efficacious for the treatment of enthesitis, with a safety profile already obtained from the competed clinical studies.

Interleukin 26

IL-26 and IL-26 Receptors

IL-26 belongs to IL-10 family of proteins which includes IL-10, IL-19, IL-20, IL-24, IL-22, IL-26, IL-28 and IL-29. IL-26 is mainly expressed by RORγt-positive/IL-17-producing Th17 and γδ T cells. IL-26 is often co-expressed with IL-22 in activated T cells, especially Th17 cells (Donnelly et al. 2010; Ouyang et al. 2011; Pene et al. 2008; Wilson et al. 2007). It is also expressed in a cell population called NK-22 cells, which seem to play a role in human mucosal immunity (Cella et al. 2009). A recent study revealed that ILC3 cells from human tonsil expressed high level of Il26 mRNA (Montaldo et al. 2014). In addition, synoviocytes from RA patients were reported to express IL-26 (Corvaisier et al. 2012).

The Il26 and Il22 genes are closely located in tandem orientation on chromosome 12q15, and therefore may explain their overlapping expression pattern in Th17 cells (Donnelly et al. 2010). Both IL-26 and IL-22 share the IL-10RB receptor subunit and induce STAT3 and STAT1 phosphorylation upon receptor binding (Hor et al. 2004; Sheikh et al. 2004) (Fig. 2). IL-26 and IL-22 also share common biological responses in vitro, including activation of phospho-STAT3 and induction of proinflammatory cytokines (Ouyang et al. 2011). The precise difference in their physiological role is poorly characterized largely because of the lack of IL-26 in rodent species (Braum et al. 2012; Shakhsi-Niaei et al. 2013). However, there are a variety of differences between IL-26 and IL-22. Molecularly, the two cytokines share very low amino acid homology (<20 %). IL-26 has a strong cationic nature (pI = 10.7) that may allow it to stick to the negatively charged surface of cells and may allow it to function as a long-acting cytokine (Donnelly et al. 2010; Knappe et al. 2000), whereas IL-22 is neutral (pI = 7.2) and could be short lived. IL-26 is predicted to form a dimer structure, while IL-22 acts as a monomer. The receptors of the two cytokines are IL-10RB/IL-20RA for IL-26 and IL-10RB/IL-22RA for IL-22, indicating they share IL-10RB subunit. Both IL-20RA and IL-22RA are expressed on epithelial cells; however, IL-20RA is expressed on skin, lung, and colon, while IL-22RA is highly expressed on liver, kidney, and pancreas. IL-20RA also serves as a receptor subunit for IL-19, IL-20 and IL-24 as well, and there may be interplay between IL-26 and other IL-20RA-binding cytokines. IL-22 can be bound by IL-22 binding proteins, which adds another layer of regulation, while there has been no such proteins identified for IL-26 (Dumoutier et al. 2001). The expression kinetics may also differ between the two cytokines. A recent study in a model of cow mammary gland inflammation suggested a difference in the in vivo kinetics between IL-26 and other Th17 cytokines including IL-22 (Rainard et al. 2013). Thus, it is likely that IL-26 and IL-22 have different roles in both the normal state and in the context of disease.
Fig. 2

IL-22 and IL-26 signaling pathways. The two cytokines share the same receptor subunit IL-10RB, but differ in their alpha receptor subunits. Both IL-22 and IL-26 induce the phosphorylations STAT1 and STAT3, but they may trigger other different signaling pathways which result in the induction of different sets of genes

Blocking IL-26 Pathway for Autoimmune Inflammatory Diseases

IL-26 induces the production of the proinflammatory cytokines such as IL-1β, IL-6, and TNF-α in human monocytes, and also upregulates the expression of the chemokine CCL20 (Corvaisier et al. 2012). It has been shown to induce the expression of IL-8 and TNF-α in a colon epithelial cell line as well (Dambacher et al. 2009). IL-26 expressed by the synovial fibroblasts in the joints of RA patients acts on monocytes to produce IL-1β, which in turn enhances the generation of Th17 cells (Corvaisier et al. 2012). Thus, IL-26 may play a pathogenic role in autoimmune diseases (Figs. 1, 2). Indeed, in ulcerative colitis the single nucleotide polymorphism rs2870946 located in the Il26 gene showed significant association with the disease (Silverberg et al. 2009), and elevated expression of Il26 mRNA was observed in the colon in a study of pediatric-onset ulcerative colitis (Kugathasan et al. 2008). In Crohn’s disease patients, the number of infiltrating IL-26 positive Th17 cells was increased in the colon; IL-26 mRNA expression was up-regulated, and the expression of IL-26 correlated with the expression of proinflammatory cytokines including IL-8 (Dambacher et al. 2009). Hence, IL-26 may play a pathogenic role in IBD by directly affecting the epithelial cell biology, recruiting neutrophils, and producing proinflammatory cytokines. In RA, a polymorphic marker located 3 kb downstream of the Il26 gene was significantly associated with RA in women (Vandenbroeck et al. 2003). The synovium from RA patients showed high staining of IL-26 protein in immunohistochemistry, and synovial fibroblasts from RA patients expressed a high level of IL-26 (Corvaisier et al. 2012). In multiple sclerosis, the genetic region of Il26 and Ifng is correlated with susceptibility to the disease in females but not in males (Goris et al. 2002). In Psoriasis, a transcriptional analysis of lesion and non-lesion skin demonstrated that Th17-derived cytokines, including IL-26, were more highly expressed in lesions than in normal skin (Wilson et al. 2007). In summary, these data support that overexpressed IL-26 protein could act as proinflammatory cytokine and contribute to the development of several autoimmune diseases. Though currently there is no published clinical trial modulating IL-26 activity, accumulating evidence suggests that IL-26 is an interesting drug target to pursue (Fig. 1).


Beside the cytokines discussed above, there is growing interest in the pathogenic effects of GM-CSF-producing Th17 cells in the development of autoimmune and inflammatory diseases (Shiomi and Usui 2015). Recent studies reported that GM-CSF is critical for the pathogenicity of Th17 cells (Codarri et al. 2011; El-Behi et al. 2011). This has led to the development of anti-GM-CSF and anti-GM-CSF receptor neutralizing antibodies (Burmester et al. 2013; Dale et al. 2014). The results from the future clinical trials of these therapeutics warrant attention.


Th17 cells produce multiple cytokines, and thus exert pleiotropic effects on host protection while playing a pathogenic role in disease pathology. Outcomes from clinical trials targeting individual Th17 cytokines will reveal the differential roles of the cytokines in the context of autoimmune diseases. Thus, targeting the right Th17 cytokines in the right disease contexts should enable effective modulation of the diseases while minimizing adverse effects on host protection.


  1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A et al (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942–949PubMedCrossRefGoogle Scholar
  2. Aujla SJ, ChanYR Zheng M et al (2008) IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14:275–281PubMedCentralPubMedCrossRefGoogle Scholar
  3. Baeten D, Baraliakos X, Braun J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713PubMedCrossRefGoogle Scholar
  4. Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRefGoogle Scholar
  5. Boniface K, Bernard FX, Garcia M et al (2005) IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174:3695–3702PubMedCrossRefGoogle Scholar
  6. Braum O, Pirzer H, Fickenscher H (2012) Interleukin-26, a highly cationic T-cell cytokine targeting epithelial cells. Antiinflamm Antiallergy Agents Med Chem 11:221–229PubMedCrossRefGoogle Scholar
  7. Burmester GR, Weinblatt ME, McInnes IB et al (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72:1445–1452PubMedCentralPubMedCrossRefGoogle Scholar
  8. Cella M, Fuchs A, Vermi W et al (2009) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457:722–725PubMedCentralPubMedCrossRefGoogle Scholar
  9. Ciofani M, Madar A, Galan C et al (2012) A validated regulatory network for Th17 cell specification. Cell 151:289–303PubMedCentralPubMedCrossRefGoogle Scholar
  10. Codarri L, Gyulveszi G, Tosevski V et al (2011) RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12:560–567PubMedCrossRefGoogle Scholar
  11. Corvaisier M, Delneste Y, Jeanvoine H et al (2012) IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 10:e1001395PubMedCentralPubMedCrossRefGoogle Scholar
  12. Crellin NK, Trifari S, Kaplan CD et al (2010) Regulation of cytokine secretion in human CD127(+) LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 33:752–764PubMedCrossRefGoogle Scholar
  13. Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10:479–489PubMedCrossRefGoogle Scholar
  14. Cupedo T, Crellin NK, Papazian N et al (2009) Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 10:66–74PubMedCrossRefGoogle Scholar
  15. Da Rocha LF, Duarte AL, Dantas AT et al (2012) Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol 39:1320–1325PubMedCrossRefGoogle Scholar
  16. Dale J, Purves D, McConnachie A et al (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res 66:19–26CrossRefGoogle Scholar
  17. Dambacher J, Beigel F, Zitzmann K et al (2009) The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58:1207–1217PubMedCrossRefGoogle Scholar
  18. Dige A, Stoy S, Rasmussen TK et al (2013) Increased levels of circulating Th17 cells in quiescent versus active Crohn’s disease. J Crohns Colitis 7:248–255PubMedCrossRefGoogle Scholar
  19. Donnelly RP, Sheikh F, Dickensheets H et al (2010) Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev 21:393–401PubMedCentralPubMedCrossRefGoogle Scholar
  20. Duhen T, Geiger R, Jarrossay D et al (2009) Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 10:857–863PubMedCrossRefGoogle Scholar
  21. Dumoutier L, Lejeune D, Colau D et al (2001) Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 166:7090–7095PubMedCrossRefGoogle Scholar
  22. El-Behi M, Ciric B, Dai H et al (2011) The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12:568–575PubMedCentralPubMedCrossRefGoogle Scholar
  23. Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMedCentralPubMedGoogle Scholar
  24. Fossiez F, Djossou O, Chomarat P et al (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183:2593–2603PubMedCrossRefGoogle Scholar
  25. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567PubMedCentralPubMedCrossRefGoogle Scholar
  26. Genovese MC, Van den Bosch F, Roberson SA et al (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929–939PubMedCrossRefGoogle Scholar
  27. Genovese MC, Durez P, Richards HB et al (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863–869PubMedCrossRefGoogle Scholar
  28. Goris A, Heggarty S, Marrosu MG et al (2002) Linkage disequilibrium analysis of chromosome 12q14–15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility. Genes Immun 3:470–476PubMedCrossRefGoogle Scholar
  29. Gu Y, Yang J, Ouyang X et al (2008) Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 38:1807–1813PubMedCentralPubMedCrossRefGoogle Scholar
  30. Happel KI, Dubin PJ, Zheng M et al (2005) Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 202:761–769PubMedCentralPubMedCrossRefGoogle Scholar
  31. Hor S, Pirzer H, Dumoutier L et al (2004) The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 279:33343–33351PubMedCrossRefGoogle Scholar
  32. Huang W, Na L, Fidel PL et al (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631PubMedCrossRefGoogle Scholar
  33. Hueber W, Patel DD, Dryja T et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72PubMedCrossRefGoogle Scholar
  34. Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–1700PubMedCrossRefGoogle Scholar
  35. Ikeuchi H, Kuroiwa T, Hiramatsu N et al (2005) Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 52:1037–1046PubMedCrossRefGoogle Scholar
  36. Ivanov II, McKenzie BS, Zhou L et al (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133PubMedCrossRefGoogle Scholar
  37. Kamanaka M, Huber S, Zenewicz LA et al (2011) Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 208:1027–1040PubMedCentralPubMedCrossRefGoogle Scholar
  38. Khader SA, Bell GK, Pearl JE et al (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369–377PubMedCrossRefGoogle Scholar
  39. Knappe A, Hor S, Wittmann S et al (2000) Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol 74:3881–3887PubMedCentralPubMedCrossRefGoogle Scholar
  40. Koenders MI, Kolls JK, Oppers-Walgreen B et al (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52:3239–3247PubMedCrossRefGoogle Scholar
  41. Kondo T, Takata H, Matsuki F et al (2009) Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 182:1794–1798PubMedCrossRefGoogle Scholar
  42. Korn T, Bettelli E, Oukka M et al (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517PubMedCrossRefGoogle Scholar
  43. Kotenko SV, Izotova LS, Mirochnitchenko OV et al (2001) Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276:2725–2732PubMedCrossRefGoogle Scholar
  44. Kugathasan S, Baldassano RN, Bradfield JP et al (2008) Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 40:1211–1215PubMedCentralPubMedCrossRefGoogle Scholar
  45. Kumar P, Thakar MS, Ouyang W et al (2013) IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 6:69–82PubMedCrossRefGoogle Scholar
  46. Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371:326–338PubMedCrossRefGoogle Scholar
  47. Langrish CL, Chen Y, Blumenschein WM et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedCentralPubMedCrossRefGoogle Scholar
  48. Leipe J, Schramm MA, Grunke M et al (2011) Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 70:1453–1457PubMedCrossRefGoogle Scholar
  49. Lejeune D, Dumoutier L, Constantinescu S et al (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277:33676–33682PubMedCrossRefGoogle Scholar
  50. Leonardi C, Matheson R, Zachariae C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190–1199PubMedCrossRefGoogle Scholar
  51. Leppkes M, Becker C, Ivanov II et al (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257–267PubMedCrossRefGoogle Scholar
  52. Li D, Guo B, Wu H et al (2015) Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity 20:1–9CrossRefGoogle Scholar
  53. Liang SC, Tan XY, Luxenberg DP et al (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279PubMedCentralPubMedCrossRefGoogle Scholar
  54. Lock C, Hermans G, Pedotti R et al (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500–508PubMedCrossRefGoogle Scholar
  55. Lubberts E (2015) The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11:415–429PubMedCrossRefGoogle Scholar
  56. Lubberts E, Joosten LA, van de Loo FA et al (2002) Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 51:102–104PubMedCrossRefGoogle Scholar
  57. Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659PubMedCrossRefGoogle Scholar
  58. Martin B, Hirota K, Cua DJ et al (2009) Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31:321–330PubMedCrossRefGoogle Scholar
  59. Martin DA, Churchill M, Flores-Suarez L et al (2013) A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 15:R164PubMedCentralPubMedCrossRefGoogle Scholar
  60. Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27:127–133PubMedCrossRefGoogle Scholar
  61. Michel ML, Keller AC, Paget C et al (2007) Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204:995–1001PubMedCentralPubMedCrossRefGoogle Scholar
  62. Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763–776PubMedCrossRefGoogle Scholar
  63. Montaldo E, Teixeira-Alves LG, Glatzer T et al (2014) Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells. Immunity 41:988–1000PubMedCrossRefGoogle Scholar
  64. Ouyang W, Rutz S, Crellin NK et al (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109PubMedCrossRefGoogle Scholar
  65. Papp KA, Leonardi C, Menter A et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366:1181–1189PubMedCrossRefGoogle Scholar
  66. Pene J, Chevalier S, Preisser L et al (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180:7423–7430PubMedCrossRefGoogle Scholar
  67. Rainard P, Cunha P, Bougarn S et al (2013) T helper 17-associated cytokines are produced during antigen-specific inflammation in the mammary gland. PLoS ONE 8:e63471PubMedCentralPubMedCrossRefGoogle Scholar
  68. Res PC, Piskin G, de Boer OJ et al (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5:e14108PubMedCentralPubMedCrossRefGoogle Scholar
  69. Robinson KM, Manni ML, Biswas PS et al (2013) Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders. Curr Allergy Asthma Rep 13:587–595PubMedCrossRefGoogle Scholar
  70. Rouvier E, Luciani MF, Mattei MG et al (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150:5445–5456PubMedGoogle Scholar
  71. Rudner XL, Happel KI, Young EA et al (2007) Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 75:3055–3061PubMedCentralPubMedCrossRefGoogle Scholar
  72. Sarkar S, Fox DA (2010) Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 36:345–366PubMedCrossRefGoogle Scholar
  73. Sarkar S, Zhou X, Justa S et al (2013) Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum 65:960–971PubMedCentralPubMedCrossRefGoogle Scholar
  74. Seiderer J, Elben I, Diegelmann J et al (2008) Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 14:437–445PubMedCrossRefGoogle Scholar
  75. Shakhsi-Niaei M, Drogemuller M, Jagannathan V et al (2013) IL26 gene inactivation in Equidae. Anim Genet 44:770–772PubMedCrossRefGoogle Scholar
  76. Sheikh F, Baurin VV, Lewis-Antes A et al (2004) Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 172:2006–2010PubMedCrossRefGoogle Scholar
  77. Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4CD8 entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRefGoogle Scholar
  78. Shiomi A, Usui T (2015) Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm 2015:568543PubMedCentralPubMedCrossRefGoogle Scholar
  79. Silverberg MS, Cho JH, Rioux JD et al (2009) Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 41:216–220PubMedCentralPubMedCrossRefGoogle Scholar
  80. Skepner J, Ramesh R, Trocha M et al (2014) Pharmacologic inhibition of RORgammat regulates Th17 Signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol 192:2564–2575PubMedCrossRefGoogle Scholar
  81. Skepner J, Trocha M, Ramesh R et al (2015) In vivo regulation of gene expression and Th17 differentiation by RORgammat inverse agonists. Immunology 145:347–356PubMedCrossRefGoogle Scholar
  82. Sonnenberg GF, Fouser LA, Artis D (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12:383–390PubMedCrossRefGoogle Scholar
  83. Sugimoto K, Ogawa A, Mizoguchi E et al (2008) IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118:534–544PubMedCentralPubMedGoogle Scholar
  84. Sutton CE, Lalor SJ, Sweeney CM et al (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331–341PubMedCrossRefGoogle Scholar
  85. Suurmond J, Dorjee AL, Boon MR et al (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13:R150PubMedCentralPubMedCrossRefGoogle Scholar
  86. Symons A, Budelsky AL, Towne JE (2012) Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol 5:4–6PubMedCrossRefGoogle Scholar
  87. Takatori H, Kanno Y, Watford WT et al (2009) Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206:35–41PubMedCentralPubMedCrossRefGoogle Scholar
  88. Trifari S, Kaplan CD, Tran EH et al (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864–871PubMedCrossRefGoogle Scholar
  89. Uyttenhove C, Van SJ (2006) Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 36:2868–2874PubMedCrossRefGoogle Scholar
  90. Van Belle AB, de Heusch M, Lemaire MM et al (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188:462–469PubMedCrossRefGoogle Scholar
  91. Vandenbroeck K, Cunningham S, Goris A et al (2003) Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis Rheum 48:2773–2778PubMedCrossRefGoogle Scholar
  92. Veldhoen M, Hocking RJ, Atkins CJ et al (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189PubMedCrossRefGoogle Scholar
  93. Wilson NJ, Boniface K, Chan JR et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950–957PubMedCrossRefGoogle Scholar
  94. Witte E, Witte K, Warszawska K et al (2010) Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 21:365–379PubMedCrossRefGoogle Scholar
  95. Wolk K, Kunz S, Asadullah K et al (2002) Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168:5397–5402PubMedCrossRefGoogle Scholar
  96. Wolk K, Kunz S, Witte E et al (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254PubMedCrossRefGoogle Scholar
  97. Wolk K, Witte E, Wallace E et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309–1323PubMedCrossRefGoogle Scholar
  98. Wolk K, Witte E, Hoffmann U et al (2007) IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J Immunol 178:5973–5981PubMedCrossRefGoogle Scholar
  99. Wolk K, Haugen HS, Xu W et al (2009) IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 87:523–536PubMedCrossRefGoogle Scholar
  100. Xie MH, Aggarwal S, Ho WH et al (2000) Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2–4 and IL-22R. J Biol Chem 275:31335–31339PubMedCrossRefGoogle Scholar
  101. Yang J, Skepner J, Mark T et al (2013) Small molecule inhibitors targeting the Th17 cell transcription factor RORgammat for the treatment of autoimmune diseases. J Clin Cell Immunol 4:e111CrossRefGoogle Scholar
  102. Yao Z, Fanslow WC, Seldin MF et al (1995a) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:811–821PubMedCrossRefGoogle Scholar
  103. Yao Z, Painter SL, Fanslow WC et al (1995b) Human IL-17: a novel cytokine derived from T cells. J Immunol 155:5483–5486PubMedGoogle Scholar
  104. Ye P, Garvey PB, Zhang P et al (2001a) Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25:335–340PubMedCrossRefGoogle Scholar
  105. Ye P, Rodriguez FH, Kanaly S et al (2001b) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519–527PubMedCentralPubMedCrossRefGoogle Scholar
  106. Zenewicz LA, Yancopoulos GD, Valenzuela DM et al (2008) Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29:947–957PubMedCentralPubMedCrossRefGoogle Scholar
  107. Zhang L, Li JM, Liu XG et al (2011) Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 31:606–614PubMedCrossRefGoogle Scholar
  108. Zheng Y, Danilenko DM, Valdez P et al (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648–651PubMedCrossRefGoogle Scholar
  109. Zheng Y, Valdez PA, Danilenko DM et al (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14:282–289PubMedCrossRefGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2015

Authors and Affiliations

  1. 1.Tempero, GlaxoSmithKlineCambridgeUSA

Personalised recommendations